Therapy Areas: Inflammatory Diseases
Formosa Pharmaceuticals and Apotex sign Mexico licensing agreement for clobetasol propionate ophthalmic suspension
7 May 2025 - Taiwan-based Formosa Pharmaceuticals (TW:6838) announced on Tuesday that the company has entered into an exclusive licensing agreement with Apotex Inc, a Canadian pharmaceutical company, ...
Innovent reports first patient dosed in efdamrofusp alfa (IBI302) Phase 2 study in diabetic macular edema
7 May 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Tuesday the completion of first patient dosing in the Phase 2 clinical study of efdamrofusp alfa (R&...
Ananda Pharma receives TGA Acknowledgement for Phase 1 clinical trial
28 April 2025 - UK-based biopharmaceutical company Ananda Pharma plc (AQSE: ANA) ( OTCQB: ANANF) announced on Monday that its Phase I clinical trial for MRX1 has been acknowledged by Australia's ...
argenx receives positive CHMP opinion for VYVGART subcutaneous injection in CIDP treatment
28 April 2025 - Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) said on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Formosa Pharmaceuticals and Saval agree licensing deal for clobetasol propionate ophthalmic suspension
28 April 2025 - Taiwan-based Formosa Pharmaceuticals (TW:6838) announced on Friday that the company has entered into an exclusive licensing agreement with Laboratorios Saval, a Chilean pharmaceutical ...
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
24 April 2025 - China-based LakeShore Biopharma Co Ltd (Nasdaq:LSB) announced on Wednesday that it has held the 2025 CSO (Contract Sales Organisation) Annual Meeting and the launch meeting of YSJA rab...